Top stories from TTO's October newsletter:
Tom Smerdon, Interim Associate VP for Technology Transfer
TTO is pleased to announce that Tom Smerdon was appointed Interim Associate Vice President for Technology Transfer in August 2012 - as AVP he has responsibility for intellectual property and technology licensing matters across all CU campuses. Tom joined TTO in 2005 as Director of New Business Development, and since 2007 has served as Director of Licensing and New Business Development. In that role, he was involved in all aspects of technology licensing for all CU campuses, with a particular focus on start-up companies based on CU technologies, as well as shareholder and equity-related agreements for the University License Equity Holdings, Inc., which holds the private equity received in connection licenses to start-up companies.
Before joining TTO, Tom was Associate Director for The Ohio State University's Office for Technology Licensing. Prior to entering the university tech transfer arena, Tom was general counsel and director of environment, health and safety for an Ohio-based private adhesive and polymer manufacturer and before that was assistant general counsel of the Chemical Manufacturers Association in Washington, D.C. Tom is a graduate of Duke University and the University of Texas Law School.
Tom takes the place of David Allen, who left TTO in August to assume a new role at the University of Arizona.
CU Lecturer and NIST Scientist Wineland Wins Nobel
David J. Wineland, a lecturer in the CU-Boulder physics department and physicist with the National Institute of Standards and Technology (NIST) in Boulder, in early October won the 2012 Nobel Prize in physics. Wineland is internationally recognized for developing the technique of using lasers to cool ions to near absolute zero. His experiments have been used to test theories in quantum physics and may lead to the development of quantum computers. He shares the prize with Serge Haroche of France. (See also: CU-Boulder, NIST share 4 Nobel Prize winners.)
MiRagen Therapeutics - 2012 Fierce 15
MiRagen Therapeutics (a CU licensee) has claimed verdant territory in the emerging field of microRNA drug development, with a lead candidate (MGN-9103) in preclinical development that could combat heart failure while providing a weight-loss benefit and other positive metabolic effects.
Read the full newsletter, or sign up to receive a monthly email update.
10 hours ago